Abstract
Abstract In the past decade, the treatment for B-cell lymphoma has been developed largely. Rituximab, a chimeric monoclonal antibody that targets against CD20 molecule, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis. As the other anti-CD20 antibodies, there are ofatumumab and obinutuzumab, and clinical development is on going. Antibodies against CD22 and CD79b molecules are also developed for B-cell lymphoma. In addition, the inhibitors targeting apoptosis pathways, proteasome, and other pathways of B-cell lymphoma are developing as novel drugs for B-cell lymphoma. Especially, BCR pathway is one of the most crucial pathways, and ibrutinib is a small molecule, once-daily, orally available, Bruton's tyrosine kinase (BTK) inhibitor that is under development for the treatment of B cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B cell lymphoma, as well as follicular lymphoma. Here, I will discuss about development of novel drugs for malignant lymphoma in the present and the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
